Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares

Introducción: el carcinoma diferenciado de tiroides (CDT) es uno de los tipos de cáncer endocrino más comúnmente observados. En general, el pronóstico del CDT es favorable; sin embargo, los pacientes que presentan metástasis a distancia tienen peor pronóstico. La localización a distancia más frecuen...

Full description

Autores:: Torres Agredo, Liliana Patricia

Tipo de recurso:

Fecha de publicación:: 2021

Institución:: Universidad Autónoma de Bucaramanga - UNAB

Repositorio:: Repositorio UNAB

Idioma:: spa

id	UNAB2_0ba68a9bb3fc525895f58c5c8932bf0b
oai_identifier_str	oai:repository.unab.edu.co:20.500.12749/14233
network_acronym_str	UNAB2
network_name_str	Repositorio UNAB
repository_id_str
dc.title.spa.fl_str_mv	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
dc.title.translated.spa.fl_str_mv	Factors associated with complete functional imaging remission in patients with differentiated thyroid carcinoma treated with radioactive iodine for the management of lung metastases
title	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
spellingShingle	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares Medical sciences Health sciences Nuclear medicine Radiation Physiological effect Thyroid cancer Lung metastasis Radioactive iodine therapy Whole body scan Endocrine glands Thyroid diseases Carcinomas Ciencias médicas Medicina nuclear Radiación Efectos fisiológicos Glándulas endocrinas Enfermedades de las tiroides Carcinomas Ciencias de la salud Cáncer de tiroides Metástasis pulmonar Terapia yodo radioactivo Rastreo corporal total
title_short	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
title_full	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
title_fullStr	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
title_full_unstemmed	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
title_sort	Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares
dc.creator.fl_str_mv	Torres Agredo, Liliana Patricia
dc.contributor.advisor.none.fl_str_mv	Wandurraga Sánchez, Edwin Antonio Morales Avellaneda, Tatiana Camacho López, Paul Anthony
dc.contributor.author.none.fl_str_mv	Torres Agredo, Liliana Patricia
dc.contributor.cvlac.spa.fl_str_mv	Wandurraga Sánchez, Edwin Antonio [0001475567]
dc.contributor.cvlac.none.fl_str_mv	Camacho López, Paul Anthony [0000323578] Camacho López, Paul Anthony [0000323578]
dc.contributor.googlescholar.none.fl_str_mv	Camacho López, Paul Anthony [es&oi=ao] Camacho López, Paul Anthony [OvqUoOAAAAAJ]
dc.contributor.orcid.spa.fl_str_mv	Wandurraga Sánchez, Edwin Antonio [0000-0002-0529-2343]
dc.contributor.orcid.none.fl_str_mv	Camacho López, Paul Anthony [0000-0002-6233-9582] Camacho López, Paul Anthony [0000-0002-6233-9582]
dc.contributor.scopus.none.fl_str_mv	Camacho López, Paul Anthony [16047325700]
dc.contributor.researchgate.spa.fl_str_mv	Wandurraga Sánchez, Edwin Antonio [Edwin-Antonio-Wandurraga-Sanchez-2168480303]
dc.contributor.researchgate.none.fl_str_mv	Camacho López, Paul Anthony [Paul_Camacho_Lopez]
dc.contributor.apolounab.none.fl_str_mv	Camacho López, Paul Anthony [paul-anthony-camacho-lópez]
dc.contributor.linkedin.none.fl_str_mv	Camacho López, Paul Anthony [paulcamachomdepi]
dc.subject.keywords.spa.fl_str_mv	Medical sciences Health sciences Nuclear medicine Radiation Physiological effect Thyroid cancer Lung metastasis Radioactive iodine therapy Whole body scan Endocrine glands Thyroid diseases Carcinomas
topic	Medical sciences Health sciences Nuclear medicine Radiation Physiological effect Thyroid cancer Lung metastasis Radioactive iodine therapy Whole body scan Endocrine glands Thyroid diseases Carcinomas Ciencias médicas Medicina nuclear Radiación Efectos fisiológicos Glándulas endocrinas Enfermedades de las tiroides Carcinomas Ciencias de la salud Cáncer de tiroides Metástasis pulmonar Terapia yodo radioactivo Rastreo corporal total
dc.subject.lemb.spa.fl_str_mv	Ciencias médicas Medicina nuclear Radiación Efectos fisiológicos Glándulas endocrinas Enfermedades de las tiroides Carcinomas
dc.subject.proposal.spa.fl_str_mv	Ciencias de la salud Cáncer de tiroides Metástasis pulmonar Terapia yodo radioactivo Rastreo corporal total
description	Introducción: el carcinoma diferenciado de tiroides (CDT) es uno de los tipos de cáncer endocrino más comúnmente observados. En general, el pronóstico del CDT es favorable; sin embargo, los pacientes que presentan metástasis a distancia tienen peor pronóstico. La localización a distancia más frecuente de las metástasis del CDT es a nivel pulmonar y la terapia con yodo radiactivo [131I]NaI es las más adecuada para aquellas metástasis pulmonares de CDT ávidas de [131I]NaI pero que no se pueden resecar quirúrgicamente y puede aliviar la afección parcialmente o eliminar la lesión de manera efectiva. Actualmente se ha convertido en la piedra angular del tratamiento de las metástasis pulmonares del CDT y hasta la fecha, algunas investigaciones previas han discutido la eficacia del yodo radioactivo y sus factores influyentes para los pacientes con CDT con metástasis pulmonares. Objetivo: Evaluar la eficacia de la terapia con el [131I]NaI para los pacientes con CDT con metástasis pulmonares, buscando explorar los factores asociados con la remisión imagenológica funcional completa. Materiales y métodos: Se realizó un estudio de cohorte retrospectivo, incluyendo a los pacientes atendidos en un centro de medicina nuclear entre el 1 enero de 2010 al 31 de diciembre de 2019 con diagnóstico de carcinoma diferenciado de tiroides. con metástasis pulmonares, a quienes se les realizó terapia ablativa con yodo radioactivo luego de la tiroidectomía total y posteriormente se analizó la remisión imagenológica completa, mediante los hallazgos del [131I]NaI -RCT posterior a los 24 meses de tratamiento con [131I]NaI. Se tomaron las variables sociodemográficas, histopatológicas, clínicas y quirúrgicas, para establecer los factores asociados con la remisión funcional pulmonar. Resultados: De los 10 años de seguimiento se identificaron 2640 pacientes con CDT el 3,18% presentaron metástasis a nivel pulmonar, y al aplicar los criterios de inclusión - exclusión se reclutaron 54 pacientes (2,05%). En el análisis bivariado, se encontró asociaciones entre la respuesta funcional pulmonar posterior a la terapia con yodo y el tamaño tumoral mayor a 3,5 cm RR 0.56, IC (95% 0.19-1.6) p = 0,28], la presencia de extensión extratiroidea (ETE) [RR 0.53, IC (95% 0.18-1.57) p = 0,24], y tener una dosis acumulada mayor a 370 mCi (13690 MBq) [RR 3.75, IC (95% 1.13-12.34) p = 0.16]. El 42 % de los pacientes presentaron remisión completa posterior a la tercera dosis de [131I] NaI; el tener mas sesiones de terapia con yodo-radioactivo presenta una probabilidad de 4,7 veces más de presentar remisión imagenológica que el realizar menos sesiones de terapia con [131I]NaI [RR 4.7, IC (95% 1.13-12.34) p = 0.03]. Al realizar el análisis multivariado, los factores asociados con la predicción de la eficacia en la terapia con [131I]Na para CDT con metástasis pulmonares fueron la presencia de ETE y la administración de yodo radiactivo en un número de dosis > de 3 veces. Conclusiones: Este estudio indicó que uno de cada cinco pacientes con CDT con metástasis pulmonares pueden obtener una remisión completa después de la terapia con [131I]NaI. La administración de yodo radiactivo en un número de dosis > de 3 veces, es un factor indicativo de buena respuesta.
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-09-10T19:22:29Z
dc.date.available.none.fl_str_mv	2021-09-10T19:22:29Z
dc.date.issued.none.fl_str_mv	2021
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/masterThesis
dc.type.local.spa.fl_str_mv	Tesis
dc.type.redcol.none.fl_str_mv	http://purl.org/redcol/resource_type/TM
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/20.500.12749/14233
dc.identifier.instname.spa.fl_str_mv	instname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional UNAB
dc.identifier.repourl.spa.fl_str_mv	repourl:https://repository.unab.edu.co
url	http://hdl.handle.net/20.500.12749/14233
identifier_str_mv	instname:Universidad Autónoma de Bucaramanga - UNAB reponame:Repositorio Institucional UNAB repourl:https://repository.unab.edu.co
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	1. Hundahl, S., Fleming, I., Fremgen, A., & Menck, H. (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83(12), 2638-2648.doi: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 Massin, J., Savoie, J., Garnier, H., Guiraudon, G., Leger, F., & Bacourt, F. (1984). Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer, 53(4), 982-992. doi: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-e Ruegemer, J., Hay, I., Bergstralh, E., Ryan, J., Offord, K., & Gorman, C. (1988). Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*. The Journal Of Clinical Endocrinology & Metabolism, 67(3), 501-508. doi: 10.1210/jcem-67-3-501 Brown, A., Greening, W., McCready, V., Shaw, H., & Harmer, C. (1984). Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. The British Journal Of Radiology, 57(676), 323-327. doi: 10.1259/0007-1285-57-676-323 Casara, D., Rubello, D., Saladini, G., Gallo, V., Masarotto, G., & Busnardo, B. (1991). Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients. Tumori Journal, 77(5), 432-436. doi: 10.1177/030089169107700512 Samaan, N., Schultz, P., Haynie, T., & Ordonez, N. (1985). Pulmonary Metastasis of Differentiated Thyroid Carcinoma: Treatment Results in 101 Patients. The Journal Of Clinical Endocrinology & Metabolism, 60(2), 376-380. doi: 10.1210/jcem-60-2-376 Jonklaas, J., Sarlis, N., Litofsky, D., Ain, K., Bigos, S., & Brierley, J. et al. (2006). Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy. Thyroid, 16(12), 1229-1242. doi: 10.1089/thy.2006.16.1229 Lang, B., Wong, K., Cheung, C., Wan, K., & Lo, C. (2012). Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis. Annals Of Surgical Oncology, 20(4), 1329-1335. doi: 10.1245/s10434-012-2711-x Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, & Parmentier C. (1996). Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605. Mihailovic, J., Stefanovic, L., Malesevic, M., & Markoski, B. (2009). The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant Metastases. Thyroid, 19(3), 227232. doi: 10.1089/thy.2008.0186 Lee, J., & Soh, E. (2010). Differentiated Thyroid Carcinoma Presenting with Distant Metastasis at Initial Diagnosis. Annals Of Surgery, 251(1), 114-119. doi: 10.1097/sla.0b013e3181b7faf6 Fahey, T. (2007). Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. Yearbook Of Surgery, 2007, 161-163. doi: 10.1016/s00903671(08)70119-8 Shoup, M., Stojadinovic, A., Nissan, A., Ghossein, R., Freedman, S., & Brennan, M. et al. (2003). Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. Journal Of The American College Of Surgeons, 197(2), 191-197. doi: 10.1016/s1072-7515(03)00332-6 Benbassat, C., Mechlis-Frish, S., & Hirsch, D. (2006). Clinicopathological Characteristics and Long-term Outcome in Patients with Distant Metastases from Differentiated Thyroid Cancer. World Journal Of Surgery, 30(6), 1088-1095. doi: 10.1007/s00268-005-0472-4 Huang, I., Chou, F., Liu, R., Tung, S., Chen, J., & Kuo, M. et al. (2012). Longterm outcomes of distant metastasis from differentiated thyroid carcinoma. Clinical Endocrinology, 76(3), 439-447. doi: 10.1111/j.13652265.2011.04231.x Wartofsky, L., & Van Nostrand, D. (2012). Radioiodine treatment of welldifferentiated thyroid cancer. Endocrine, 42(3), 506-513. doi: 10.1007/s12020012-9729-5 . Tumino, D., Frasca, F., & Newbold, K. (2017). Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Frontiers In Endocrinology, 8. doi: 10.3389/fendo.2017.00312 Robbins R., Schlumberger M.( 2005). The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46:28S–37S Casara, D., Rubello, D., Saladini, G., Gallo, V., Masarotto, G., & Busnardo, B. (1991). Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients. Tumori Journal, 77(5), 432-436. doi: 10.1177/030089169107700512 . Dinneen, S. (1995). Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. Journal Of Clinical Endocrinology & Metabolism, 80(7), 2041-2045. doi: 10.1210/jc.80.7.2041 Hindié, E., Mellière, D., Lange, F., Hallaj, I., de Labriolle-Vaylet, C., & Jeanguillaume, C. et al. (2003). Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis. European Journal Of Nuclear Medicine And Molecular Imaging, 30(7), 974-981. doi: 10.1007/s00259-0031174-5 Lin, J., Chao, T., Chou, S., & Hsueh, C. (2004). Papillary Thyroid Carcinomas with Lung Metastases. Thyroid, 14(12), 1091-1096. doi: 10.1089/thy.2004.14.1091 Pacini, F., Cetani, F., Miccoli, P., Mancusi, F., Ceccarelli, C., & Lippi, F. et al. (1994). Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal Of Surgery, 18(4), 600-604. doi: 10.1007/bf00353775 Song, H., Qiu, Z., Shen, C., Wei, W., & Luo, Q. (2015). Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. European Journal Of Endocrinology, 173(3), 399-408. doi: 10.1530/eje15-0296 Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., & Travagli, J. et al. (2006). Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. The Journal Of Clinical Endocrinology & Metabolism, 91(8), 2892-2899. doi: 10.1210/jc.2005-2838. Pittas, A., Adler, M., Fazzari, M., Tickoo, S., Rosai, J., Larson, S., & Robbins, R. (2000). Bone Metastases from Thyroid Carcinoma: Clinical Characteristics and Prognostic Variables in One Hundred Forty-Six Patients. Thyroid, 10(3), 261268. doi: 10.1089/thy.2000.10.261 . Mihailovic, J., Stefanovic, L., Malesevic, M., & Markoski, B. (2009). The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant Metastases. Thyroid, 19(3), 227232. doi: 10.1089/thy.2008.0186 Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli ME., & Busnardo B. (1993). Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626–1631 Sampson, E., Brierley, J., Le, L., Rotstein, L., & Tsang, R. (2007). Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer, 110(7), 14511456. doi: 10.1002/cncr.22956 Hwang, M., Lee, E., & Yang, J. (2014). Nasolacrimal Duct Obstruction after Radioactive Iodine Therapy for Thyroid Cancer. Journal Of The Korean Ophthalmological Society, 55(1), 1. doi: 10.3341/jkos.2014.55.1.1 Kloos, R., Duvuuri, V., Jhiang, S., Cahill, K., Foster, J., & Burns, J. (2002). Nasolacrimal Drainage System Obstruction from Radioactive Iodine Therapy for Thyroid Carcinoma. The Journal Of Clinical Endocrinology & Metabolism, 87(12), 5817-5820. doi: 10.1210/jc.2002-020210 Mandel, S., & Mandel, L. (2003). Radioactive Iodine and the Salivary Glands. Thyroid, 13(3), 265-271. doi: 10.1089/105072503321582060 Vargas H., Herrera ,J., Meza, I., & Agredo, V. (2015). Epidemiología del Cáncer de Tiroides. Medicina, 37(2),140-163.: http://revistamedicina.net/ojsanm/index.php/Medicina/article/view/109-4 Xing, M. (2010). Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular And Cellular Endocrinology, 321(1), 86-93. doi: 10.1016/j.mce.2009.10.012 Lim, H., Devesa, S., Sosa, J., Check, D., & Kitahara, C. (2017). Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA, 317(13), 1338-1348 doi: 10.1001/jama.2017.2719 Olaleye, O., Ekrikpo, U., Moorthy, R., Lyne, O., Wiseberg, J., Black, M., & Mitchell, D. (2010). Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006. European Archives Of Oto-RhinoLaryngology, 268(6), 899-906. doi: 10.1007/s00405-010-1416-7 Reynolds, R., Weir, J., Stockton, D., Brewster, D., Sandeep, T., & Strachan, M. (2005). Changing trends in incidence and mortality of thyroid cancer in Scotland. Clinical Endocrinology, 62(2), 156-162. doi: 10.1111/j.13652265.2004.02187.x Hayashi, Y., Lagarde, F., Tsuda, N., Funamoto, S., Preston, D., & Koyama, K. et al. (2010). Papillary microcarcinoma of the thyroid among atomic bomb survivors. Cancer, 116(7), 1646-1655. doi: 10.1002/cncr.24872 Rumyantsev, P., Saenko, V., Ilyin, A., Stepanenko, V., Rumyantseva, U., & Abrosimov, A. et al. (2011). Radiation Exposure Does Not Significantly Contribute to the Risk of Recurrence of Chernobyl Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism, 96(2), 385-393. doi: 10.1210/jc.20101634 Greenspan, B. (2018). Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits. Journal Of Clinical Oncology, 36(18), 1785-1787. doi: 10.1200/jco.2018.78.6384 Pitoia, F., & Miyauchi, A. (2016). 2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer and Their Implementation in Various Care Settings. Thyroid, 26(2), 319-321. doi: 10.1089/thy.2015.0530 Haugen, B. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer, 123(3), 372-381. doi: 10.1002/cncr.30360 Van Nostrand, D. (2009). The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer. Thyroid, 19(12), 1381-1391. doi: 10.1089/thy.2009.1611 Haugen, B., Alexander, E., Bible, K., Doherty, G., Mandel, S., & Nikiforov, Y. et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1-133. doi: 10.1089/thy.2015.0020 Chala, A., Franco, H., Aguilar, C., & Cardona, J. (2010). Estudio descriptivo de doce años de cáncer de tiroides, Manizales, Colombia. Rev Colomb Cir,25,276289 Rojas,W., Vivas-Díaz, J. (2011). Cáncer de tiroides: Características clínicas e histopatológicas servicio de endocrinología, Hospital de San José Bogotá DC, 2000-2010. Repert.med.cir, 20(3),177-184 Cuervo, JA., Osorio, K., Romero, AE., Olaya, N.(2013).Caracterización clínica e histopatológica del carcinoma papilar de tiroides en el Instituto Nacional de Cancerología E.S.E., Bogotá-Colombia durante los años 2006 a 2012. Rev Col Cancerol,17(4),188 Vargas, H., Herrera, J., Meza, I., & Agredo, Delgado, V. (2015). Cáncer de Tiroides e Indicaciones de Tiroidectomía. Medicina, 37(2), 109-121 Mantilla-Reinaud A., Vesga-Angarita BE., Insuasty- Enríquez JS., (2006). Registro de cáncer, Unidad de Oncología, Hospital Universitario Ramón González Valencia, Bucaramanga, Colombia (1996 – 1999). MedUNAB,9,14-19. Rojas-Castillo, JC., Niño, DC., Wandurraga-Sánchez, EA., García, ME., Camacho PA., Roa, JA., Sarmiento, JG. (2015). Descripción de los hallazgos histopatológicos en la terapia inicial del cáncer de tiroides en un centro de referencia en Bucaramanga, Colombia. Rev ACE, 2(1): 40-43. Hansen, K., Timp, W., Bravo, H., Sabunciyan, S., Langmead, B., & McDonald, O. et al. (2011). Increased methylation variation in epigenetic domains across cancer types. Nature Genetics, 43(8), 768-775. doi: 10.1038/ng.865 Furuya, F., Shimura, H., Suzuki, H., Taki, K., Ohta, K., Haraguchi, K., Kobayashi, T. (2004). Histone deacetylase inhibitors restore radioiodine uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroid peroxidase and thyroglobulin. Endocrinology, 145, 2865-2875 Kondo, Y. (2009). Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers. Yonsei Medical Journal, 50(4), 455. http://doi.org/10.3349/ymj.2009.50.4.455 Pugliese, M., Fortunati, N., Germano, A., Asioli, S., Marano, F., Palestini, N., Catalano, M. G. (2013). Histone Deacetylase Inhibition Affects Sodium Iodide Symporter Expression and Induces 131 I Cytotoxicity in Anaplastic Thyroid Cancer Cells. Thyroid, 23(7), 838-846. http://doi.org/10.1089/thy.2012.0359 Vu-Phan, D., & Koenig, R. J. (2014). Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol, 386(1-2), 55-66. doi: 10.1016/j.mce.2013.07.030 Russo, D., Damante, G., Puxeddu, E., Durante, C., & Filetti, S. (2011). Epigenetics of thyroid cancer and novel therapeutic targets. Journal of Molecular Endocrinology, 46(3), R73-R81. http://doi.org/10.1530/JME-10-0150 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol [Internet]. 2010;17(6):1471–4. Available from: http://www.springerlink.com/index/10.1245/s10434-010-0985-4 . Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39(8):699–706. Aschebrook-Kilfoy, B., Grogan, R., Ward, M., Kaplan, E., & Devesa, S. (2013). Follicular Thyroid Cancer Incidence Patterns in the United States, 1980– 2009. Thyroid, 23(8), 1015-1021. doi: 10.1089/thy.2012.0356 Uribe Pérez, C., Serrano Gómez, S., & Hormiga Sánchez, C. (2018). Incidencia y mortalidad por cáncer en Bucaramanga, Colombia. 2008-2012. Colombia Médica, 49(1), 73-80 Bogdanova, T., Zurnadzhy, L., Greenebaum, E., McConnell, R., Robbins, J., & Epstein, O. et al. (2006). A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident. Cancer, 107(11), 2559-2566. doi: 10.1002/cncr.22321 Fagin, J. (2004). How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal Of Endocrinology, 183(2), 249-256. doi: 10.1677/joe.1.05895 Kondo, T., Ezzat, S., & Asa, S. (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 6(4), 292-306. doi: 10.1038/nrc1836 Suh, C., Baek, J., Choi, Y., & Lee, J. (2016). Performance of CT in the Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. American Journal Of Neuroradiology, 38(1), 154-161. doi: 10.3174/ajnr.a4967 Ahn, J., Lee, J., Yi, J., Shong, Y., Hong, S., & Lee, D. et al. (2008). Diagnostic Accuracy of CT and Ultrasonography for Evaluating Metastatic Cervical Lymph Nodes in Patients with Thyroid Cancer. World Journal Of Surgery, 32(7), 15521558. doi: 10.1007/s00268-008-9588-7 Noguchi, S., Noguchi, A., & Murakami, N. (1970). Papillary carcinoma of the thyroid I. Developing pattern of metastasis. Cancer, 26(5), 1053-1060. doi: 10.1002/1097-0142(197011)26:5<1053::aid-cncr2820260513>3.0.co;2-x Anda, E., Pineda, J., Toni, M., & Galofré, J. (2016). Enfermedad nodular tiroidea. Medicine - Programa De Formación Médica Continuada Acreditado, 12(13), 713-721. doi: 10.1016/j.med.2016.06.001 Hegedüs, L.(2004).The Thyroid Nodule. N Engl J Med 351(17):1764–71. Doi: 10.1056/NEJMcp031436 Kwak, J., Han, K., Yoon, J., Moon, H., Son, E., & Park, S. et al. (2011). Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology, 260(3), 892-899. doi: 10.1148/radiol.11110206 Velasco L, S., Solar G, A., Cruz O, F., Quintana F, J., León R, A., Mosso G, L., & Fardella, C. (2007). Tiroglobulina y sus limitaciones en el seguimiento del carcinoma diferenciado del tiroides: Report of two cases. Revista Médica De Chile, 135(4). doi: 10.4067/s0034-98872007000400014 Nixon, I., Whitcher, M., Palmer, F., Shaha, A., Shah, J., Patel, S., & Ganly, I. (2012). The Impact of Distant Metastases at Presentation on Prognosis in Patients Differentiated Carcinoma of the Thyroid Gland. Thyroid, 120514113505007. doi: 10.1089/thy.2011-0535 Henriques de Figueiredo, B., Godbert, Y., Soubeyran, I., Carrat, X., Lagarde, P., & Cazeau, A. et al. (2014). Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients. Thyroid, 24(2), 270-276. doi: 10.1089/thy.2013.0061 Elisei, R., Agate, L., Viola, D., Matrone, A., Biagini, A., & Molinaro, E. (2014). How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. Endocrinology And Metabolism Clinics Of North America, 43(2), 331-344. doi: 10.1016/j.ecl.2014.02.002 Ilgan, S., Karacalioglu, A., Atac, G., Arslan, N., Ozturk, E., & Gunalp, B. et al. (2004). Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging, 31(6), 825-830. doi: 10.1007/s00259-0041460-x Ota, N., Kato, K., Iwano, S., Ito, S., Abe, S., & Fujita, N. et al. (2014). Comparison of 18 F-fluoride PET/CT,18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. The British Journal Of Radiology, 87(1034), 20130444. doi: 10.1259/bjr.20130444 Ito, S., Kato, K., Ikeda, M., Iwano, S., Makino, N., & Tadokoro, M. et al. (2007). Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer. Journal Of Nuclear Medicine, 48(6), 889-895. doi: 10.2967/jnumed.106.039479 Salvatori, M., Biondi, B., & Rufini, V. (2015). IMAGING IN ENDOCRINOLOGY: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. European Journal Of Endocrinology, 173(3), R115-R130. doi: 10.1530/eje-15-0066 Leboulleux, S., Schroeder, P., Schlumberger, M., & Ladenson, P. (2007). The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism, 3(2), 112-121. doi: 10.1038/ncpendmet0402 Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J., & Talbot, M. et al. (2010). Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocrine Related Cancer, 18(1), 159-169. doi: 10.1677/erc-10-0233 Robbins, R., Wan, Q., Grewal, R., Reibke, R., Gonen, M., & Strauss, H. et al. (2006). Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. The Journal Of Clinical Endocrinology & Metabolism, 91(2), 498-505. doi: 10.1210/jc.2005-1534 Olaleye, O., Ekrikpo, U., Moorthy, R., Lyne, O., Wiseberg, J., Black, M., & Mitchell, D. (2010). Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006. European Archives Of Oto-RhinoLaryngology, 268(6), 899-906. doi: 10.1007/s00405-010-1416-7 Reynolds, R., Weir, J., Stockton, D., Brewster, D., Sandeep, T., & Strachan, M. (2005). Changing trends in incidence and mortality of thyroid cancer in Scotland. Clinical Endocrinology, 62(2), 156-162. doi: 10.1111/j.13652265.2004.02187.x SPECKER, B., HO, M., SPERLING, M., LADENSON, P., & ROSS, D. et al. (1998). Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid, 8(9), 737-744. doi: 10.1089/thy.1998.8.737 Carhill, A., Litofsky, D., Ross, D., Jonklaas, J., Cooper, D., & Brierley, J. et al. (2015). Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987–2012. The Journal Of Clinical Endocrinology & Metabolism, 100(9), 3270-3279. doi: 10.1210/jc.2015-1346 Biondi, B., & Cooper, D. (2010). Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer. Thyroid, 20(2), 135146. doi: 10.1089/thy.2009.0311 Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., & Ford, R. et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer, 45(2), 228-247. doi: 10.1016/j.ejca.2008.10.026 R. Shaha, A., P. Shah, J., & R. Loree, T. (1997). Differentiated thyroid cancer presenting initially with distant metastasis. The American Journal Of Surgery, 174(5), 474-476. doi: 10.1016/s0002-9610(97)00158- Cady B., Rossi R.(1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery,104:947–953. doi: 10.1067/msy.1998.93106 . Cooper, D., Doherty, G., Haugen, B., Kloos, R., Lee, S., & Mandel, S. et al. (2009). Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 19(11), 1167-1214. doi: 10.1089/thy.2009.0110 Watkinson, J. (2004). The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nuclear Medicine Communications, 25(9), 897-900. doi: 10.1097/00006231-200409000-00006 . Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J., Wiersinga, W.(2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal Of Endocrinology, 154(6), 787-803. doi: 10.1530/eje.1.02158 Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M., Nistal, M., & Santisteban, P. (2006). The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane. Endocrine-Related Cancer, 13(1), 257-269. doi: 10.1677/erc.1.01119 Lin, J. (1999). Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocrine Related Cancer, 6(1), 109-115. doi: 10.1677/erc.0.0060109 R. Shaha, A., P. Shah, J., & R. Loree, T. (1997). Differentiated thyroid cancer presenting initially with distant metastasis. The American Journal Of Surgery, 174(5), 474-476. doi: 10.1016/s0002-9610(97)00158-x Mihailovic, J., Stefanovic, L., Malesevic, M., Erak, M., & Tesanovic, D. (2009). Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nuclear Medicine Communications, 30(7), 558-564. doi: 10.1097/mnm.0b013e32832cc2ab Haq, M., & Harmer, C. (2005). Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clinical Endocrinology, 63(1), 87-93. doi: 10.1111/j.1365-2265.2005.02304.x Massin, J., Savoie, J., Garnier, H., Guiraudon, G., Leger, F., & Bacourt, F. (1984). Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer, 53(4), 982-992. doi: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-e Pitoia, F., Bueno, F., & Cross, G. (2014). Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With 131IodineAvid Lung Metastasis From Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 39(9), 784-790. doi: 10.1097/rlu.0000000000000507 Mihailovic, J., Stefanovic, L., Malesevic, M., Erak, M., & Tesanovic, D. (2009). Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nuclear Medicine Communications, 30(7), 558-564. doi: 10.1097/mnm.0b013e32832cc2ab Cho, S., Choi, H., Yeom, G., Lim, J., Moon, J., & Park, D. et al. (2014). Long-Term Prognosis of Differentiated Thyroid Cancer with Lung Metastasis in Korea and Its Prognostic Factors. Thyroid, 24(2), 277-286. doi: 10.1089/thy.2012.0654 Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J., & Talbot, M. et al. (2010). Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocrine Related Cancer, 18(1), 159169. doi: 10.1677/erc-10-0233 Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., & Takamura, Y. et al. (2011). Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy. Thyroid, 21(7), 707-716. doi: 10.1089/thy.2010.0355 Lin JD, Chao TC, Chou SC, et al. Papillary thyroid carcinomas with lung metastases. Thyroid 2004;14:1091–6 Leite AK, Kulcsar MA, de Godoi Cavalheiro B, de Mello ES, Alves VA, Cernea CR, Matos LL. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER. Endocr Pract. 2017 Jan;23(1):72-78 Boria, A.J., Perez-Torres, C.J. Minimal difference between fractionated and single-fraction exposure in a murine model of radiation necrosis. Radiat Oncol 14, 144 (2019). Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G: Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16: 3100-3104. 10.1158/1078-0432.CCR-09-2891 Rubner, Y., Muth, C., Strnad, A. et al. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol 9, 89 (2014 Terashima, S., Hosokawa, Y., Tsuruga, E., Mariya, Y., & Nakamura, T. (2017). Impact of time interval and dose rate on cell survival following low-dose fractionated exposures. Journal of radiation research, 58(6), 782–790 Adamczewski, Z., Stasiołek, M., Karwowski, B., Dedecjus, M., OrszulakMichalak, D., Merecz, A., Śliwka, P. W., Puła, B., & Lewiński, A. (2015). The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro. International journal of molecular sciences, 16(7), 14608–14622 Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352–9 Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 2007;66:58–64 Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22:884–9 Li YR, Chen ST, Hsueh C, Chao TC, Ho TY, Lin JD. Risk factors of distant metastasis in the follicular variant of papillary thyroid carcinoma. J Formos Med Assoc. 2016 Aug;115(8):665-71.
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.local.spa.fl_str_mv	Abierto (Texto Completo)
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.*.fl_str_mv	Atribución-NoComercial-SinDerivadas 2.5 Colombia
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/ Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 Atribución-NoComercial-SinDerivadas 2.5 Colombia
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.coverage.spatial.spa.fl_str_mv	Bucaramanga (Santander, Colombia)
dc.coverage.temporal.spa.fl_str_mv	2010-2019
dc.coverage.campus.spa.fl_str_mv	UNAB Campus Bucaramanga
dc.publisher.grantor.spa.fl_str_mv	Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.spa.fl_str_mv	Facultad Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv	Especialización en Medicina Nuclear
institution	Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv	https://repository.unab.edu.co/bitstream/20.500.12749/14233/1/2021_Tesis_Liliana_Patricia_Torres.pdf https://repository.unab.edu.co/bitstream/20.500.12749/14233/2/2021_Licencia_Liliana_Patricia_Torres.pdf https://repository.unab.edu.co/bitstream/20.500.12749/14233/3/license.txt https://repository.unab.edu.co/bitstream/20.500.12749/14233/4/2021_Tesis_Liliana_Patricia_Torres.pdf.jpg https://repository.unab.edu.co/bitstream/20.500.12749/14233/5/2021_Licencia_Liliana_Patricia_Torres.pdf.jpg
bitstream.checksum.fl_str_mv	3b2282b0ca8f63e604aa5b0ff908d996 c5688f2125fdb04a89bceca69fa2367f 8a4605be74aa9ea9d79846c1fba20a33 850e7f21791bcbcac7b6982c006979a7 ca8ea159b6fb428e6abe6528620fde30
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional \| Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv	repositorio@unab.edu.co
_version_	1808410526563172352
spelling	Wandurraga Sánchez, Edwin Antonio5fa2192c-e67b-4220-8462-a44b20361ed6Morales Avellaneda, Tatianafeffb104-96aa-4759-8d63-1bbe91f5b894Camacho López, Paul Anthonye46d0c19-2faf-4964-80c2-bc6b94bb4127Torres Agredo, Liliana Patricia04e0d267-7863-4905-8b8b-1bae1f599c95Wandurraga Sánchez, Edwin Antonio [0001475567]Camacho López, Paul Anthony [0000323578]Camacho López, Paul Anthony [0000323578]Camacho López, Paul Anthony [es&oi=ao]Camacho López, Paul Anthony [OvqUoOAAAAAJ]Wandurraga Sánchez, Edwin Antonio [0000-0002-0529-2343]Camacho López, Paul Anthony [0000-0002-6233-9582]Camacho López, Paul Anthony [0000-0002-6233-9582]Camacho López, Paul Anthony [16047325700]Wandurraga Sánchez, Edwin Antonio [Edwin-Antonio-Wandurraga-Sanchez-2168480303]Camacho López, Paul Anthony [Paul_Camacho_Lopez]Camacho López, Paul Anthony [paul-anthony-camacho-lópez]Camacho López, Paul Anthony [paulcamachomdepi]Bucaramanga (Santander, Colombia)2010-2019UNAB Campus Bucaramanga2021-09-10T19:22:29Z2021-09-10T19:22:29Z2021http://hdl.handle.net/20.500.12749/14233instname:Universidad Autónoma de Bucaramanga - UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.coIntroducción: el carcinoma diferenciado de tiroides (CDT) es uno de los tipos de cáncer endocrino más comúnmente observados. En general, el pronóstico del CDT es favorable; sin embargo, los pacientes que presentan metástasis a distancia tienen peor pronóstico. La localización a distancia más frecuente de las metástasis del CDT es a nivel pulmonar y la terapia con yodo radiactivo [131I]NaI es las más adecuada para aquellas metástasis pulmonares de CDT ávidas de [131I]NaI pero que no se pueden resecar quirúrgicamente y puede aliviar la afección parcialmente o eliminar la lesión de manera efectiva. Actualmente se ha convertido en la piedra angular del tratamiento de las metástasis pulmonares del CDT y hasta la fecha, algunas investigaciones previas han discutido la eficacia del yodo radioactivo y sus factores influyentes para los pacientes con CDT con metástasis pulmonares. Objetivo: Evaluar la eficacia de la terapia con el [131I]NaI para los pacientes con CDT con metástasis pulmonares, buscando explorar los factores asociados con la remisión imagenológica funcional completa. Materiales y métodos: Se realizó un estudio de cohorte retrospectivo, incluyendo a los pacientes atendidos en un centro de medicina nuclear entre el 1 enero de 2010 al 31 de diciembre de 2019 con diagnóstico de carcinoma diferenciado de tiroides. con metástasis pulmonares, a quienes se les realizó terapia ablativa con yodo radioactivo luego de la tiroidectomía total y posteriormente se analizó la remisión imagenológica completa, mediante los hallazgos del [131I]NaI -RCT posterior a los 24 meses de tratamiento con [131I]NaI. Se tomaron las variables sociodemográficas, histopatológicas, clínicas y quirúrgicas, para establecer los factores asociados con la remisión funcional pulmonar. Resultados: De los 10 años de seguimiento se identificaron 2640 pacientes con CDT el 3,18% presentaron metástasis a nivel pulmonar, y al aplicar los criterios de inclusión - exclusión se reclutaron 54 pacientes (2,05%). En el análisis bivariado, se encontró asociaciones entre la respuesta funcional pulmonar posterior a la terapia con yodo y el tamaño tumoral mayor a 3,5 cm RR 0.56, IC (95% 0.19-1.6) p = 0,28], la presencia de extensión extratiroidea (ETE) [RR 0.53, IC (95% 0.18-1.57) p = 0,24], y tener una dosis acumulada mayor a 370 mCi (13690 MBq) [RR 3.75, IC (95% 1.13-12.34) p = 0.16]. El 42 % de los pacientes presentaron remisión completa posterior a la tercera dosis de [131I] NaI; el tener mas sesiones de terapia con yodo-radioactivo presenta una probabilidad de 4,7 veces más de presentar remisión imagenológica que el realizar menos sesiones de terapia con [131I]NaI [RR 4.7, IC (95% 1.13-12.34) p = 0.03]. Al realizar el análisis multivariado, los factores asociados con la predicción de la eficacia en la terapia con [131I]Na para CDT con metástasis pulmonares fueron la presencia de ETE y la administración de yodo radiactivo en un número de dosis > de 3 veces. Conclusiones: Este estudio indicó que uno de cada cinco pacientes con CDT con metástasis pulmonares pueden obtener una remisión completa después de la terapia con [131I]NaI. La administración de yodo radiactivo en un número de dosis > de 3 veces, es un factor indicativo de buena respuesta.LISTA DE SIGLAS LISTADO DE TABLAS LISTA DE ILUSTRACIONES O FIGURAS LISTA DE ANEXOS RESUMEN ABSTRACT INTRODUCCIÓN JUSTIFICACIÓN MARCO TEÓRICO ESTADO DEL ARTE PREGUNTA DE INVESTIGACIÓN OBJETIVOS METODOLOGÍA PROCEDIMIENTO DISPOSICIONES VIGENTES RESULTADOS DISCUSIÓN CONCLUSIONES FORTALEZAS Y LIMITACIONES FINANCIACIÓN Y CONFLICTOS DE INTERÉS REFERENCIASEspecializaciónIntroduction: differentiated thyroid carcinoma (DTC) is one of the most commonly observed types of endocrine cancer. In general, the prognosis for CDT is favorable; however, patients with distant metastases have a worse prognosis. The most frequent distant localization of CDT metastases is at the pulmonary level and radioactive iodine therapy [131I] NaI is the most appropriate for those pulmonary metastases of CDT avid for [131I] NaI but that cannot be surgically resected and can alleviate the condition partially or remove the injury effectively. It has now become the cornerstone of treatment for CDT lung metastases and to date, some previous research has discussed the efficacy of radioactive iodine and its influencing factors for CDT patients with lung metastases. Objective: To evaluate the efficacy of therapy with [131I] NaI for patients with DTC with pulmonary metastases, seeking to explore the factors associated with complete functional imaging remission Materials and methods: A retrospective cohort study was conducted, including patients treated at a nuclear medicine center between January 1, 2010 and December 31, 2019 with a diagnosis of differentiated thyroid carcinoma with pulmonary metastases, who underwent he performed ablative therapy with radioactive iodine after total thyroidectomy, and complete imaging remission was subsequently analyzed, using the [131I] NaI -RCT findings after 24 months of treatment with [131I] NaI. Sociodemographic, histopathological, clinical and surgical variables were taken to establish the factors associated with functional pulmonary remission. Results: Of the 10 years of follow-up, 2,640 patients with DTC were identified, 3.18% presented metastases at the lung level, and when applying the inclusion-exclusion criteria, 54 patients (2.05%) were recruited. In the bivariate analysis, associations were found between the pulmonary functional response after iodine therapy and tumor size greater than 3.5 cm RR 0.56, CI (95% 0.19-1.6) p = 0.28], the presence of extrathyroid extension (TEE) [RR 0.53, CI (95% 0.18-1.57) p = 0.24], and having a cumulative dose greater than 370 mCi (13690 MBq) [RR 3.75, CI (95% 1.13-12.34) p = 0.16]. 42% of the patients had complete remission after the third dose of [131I] NaI; having more sessions of therapy with radioactive iodine is 4.7 times more likely to present imaging remission than having fewer sessions of therapy with [131I] NaI [RR 4.7, CI (95% 1.13-12.34) p = 0.03 ]. When performing multivariate analysis, the factors associated with the prediction of efficacy in [131I] Na therapy for CDT with lung metastases were the presence of TEE and the administration of radioactive iodine in a number of doses> 3 times. Conclusions: This study indicated that one in five CDT patients with lung metastases can achieve complete remission after [131I] NaI therapy. The administration of radioactive iodine in a number of doses> 3 times is an indicative factor of a good response.Modalidad Presencialapplication/pdfspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-SinDerivadas 2.5 ColombiaFactores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonaresFactors associated with complete functional imaging remission in patients with differentiated thyroid carcinoma treated with radioactive iodine for the management of lung metastasesEspecialista en Medicina NuclearUniversidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludEspecialización en Medicina Nuclearinfo:eu-repo/semantics/masterThesisTesishttp://purl.org/redcol/resource_type/TMMedical sciencesHealth sciencesNuclear medicineRadiationPhysiological effectThyroid cancerLung metastasisRadioactive iodine therapyWhole body scanEndocrine glandsThyroid diseasesCarcinomasCiencias médicasMedicina nuclearRadiaciónEfectos fisiológicosGlándulas endocrinasEnfermedades de las tiroidesCarcinomasCiencias de la saludCáncer de tiroidesMetástasis pulmonarTerapia yodo radioactivoRastreo corporal total1. Hundahl, S., Fleming, I., Fremgen, A., & Menck, H. (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83(12), 2638-2648.doi: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1Massin, J., Savoie, J., Garnier, H., Guiraudon, G., Leger, F., & Bacourt, F. (1984). Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer, 53(4), 982-992. doi: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-eRuegemer, J., Hay, I., Bergstralh, E., Ryan, J., Offord, K., & Gorman, C. (1988). Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*. The Journal Of Clinical Endocrinology & Metabolism, 67(3), 501-508. doi: 10.1210/jcem-67-3-501Brown, A., Greening, W., McCready, V., Shaw, H., & Harmer, C. (1984). Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. The British Journal Of Radiology, 57(676), 323-327. doi: 10.1259/0007-1285-57-676-323Casara, D., Rubello, D., Saladini, G., Gallo, V., Masarotto, G., & Busnardo, B. (1991). Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients. Tumori Journal, 77(5), 432-436. doi: 10.1177/030089169107700512Samaan, N., Schultz, P., Haynie, T., & Ordonez, N. (1985). Pulmonary Metastasis of Differentiated Thyroid Carcinoma: Treatment Results in 101 Patients. The Journal Of Clinical Endocrinology & Metabolism, 60(2), 376-380. doi: 10.1210/jcem-60-2-376Jonklaas, J., Sarlis, N., Litofsky, D., Ain, K., Bigos, S., & Brierley, J. et al. (2006). Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy. Thyroid, 16(12), 1229-1242. doi: 10.1089/thy.2006.16.1229Lang, B., Wong, K., Cheung, C., Wan, K., & Lo, C. (2012). Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis. Annals Of Surgical Oncology, 20(4), 1329-1335. doi: 10.1245/s10434-012-2711-xSchlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, & Parmentier C. (1996). Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605.Mihailovic, J., Stefanovic, L., Malesevic, M., & Markoski, B. (2009). The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant Metastases. Thyroid, 19(3), 227232. doi: 10.1089/thy.2008.0186Lee, J., & Soh, E. (2010). Differentiated Thyroid Carcinoma Presenting with Distant Metastasis at Initial Diagnosis. Annals Of Surgery, 251(1), 114-119. doi: 10.1097/sla.0b013e3181b7faf6Fahey, T. (2007). Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. Yearbook Of Surgery, 2007, 161-163. doi: 10.1016/s00903671(08)70119-8Shoup, M., Stojadinovic, A., Nissan, A., Ghossein, R., Freedman, S., & Brennan, M. et al. (2003). Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. Journal Of The American College Of Surgeons, 197(2), 191-197. doi: 10.1016/s1072-7515(03)00332-6Benbassat, C., Mechlis-Frish, S., & Hirsch, D. (2006). Clinicopathological Characteristics and Long-term Outcome in Patients with Distant Metastases from Differentiated Thyroid Cancer. World Journal Of Surgery, 30(6), 1088-1095. doi: 10.1007/s00268-005-0472-4Huang, I., Chou, F., Liu, R., Tung, S., Chen, J., & Kuo, M. et al. (2012). Longterm outcomes of distant metastasis from differentiated thyroid carcinoma. Clinical Endocrinology, 76(3), 439-447. doi: 10.1111/j.13652265.2011.04231.xWartofsky, L., & Van Nostrand, D. (2012). Radioiodine treatment of welldifferentiated thyroid cancer. Endocrine, 42(3), 506-513. doi: 10.1007/s12020012-9729-5. Tumino, D., Frasca, F., & Newbold, K. (2017). Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Frontiers In Endocrinology, 8. doi: 10.3389/fendo.2017.00312Robbins R., Schlumberger M.( 2005). The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46:28S–37SCasara, D., Rubello, D., Saladini, G., Gallo, V., Masarotto, G., & Busnardo, B. (1991). Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients. Tumori Journal, 77(5), 432-436. doi: 10.1177/030089169107700512. Dinneen, S. (1995). Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. Journal Of Clinical Endocrinology & Metabolism, 80(7), 2041-2045. doi: 10.1210/jc.80.7.2041Hindié, E., Mellière, D., Lange, F., Hallaj, I., de Labriolle-Vaylet, C., & Jeanguillaume, C. et al. (2003). Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis. European Journal Of Nuclear Medicine And Molecular Imaging, 30(7), 974-981. doi: 10.1007/s00259-0031174-5Lin, J., Chao, T., Chou, S., & Hsueh, C. (2004). Papillary Thyroid Carcinomas with Lung Metastases. Thyroid, 14(12), 1091-1096. doi: 10.1089/thy.2004.14.1091Pacini, F., Cetani, F., Miccoli, P., Mancusi, F., Ceccarelli, C., & Lippi, F. et al. (1994). Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal Of Surgery, 18(4), 600-604. doi: 10.1007/bf00353775Song, H., Qiu, Z., Shen, C., Wei, W., & Luo, Q. (2015). Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. European Journal Of Endocrinology, 173(3), 399-408. doi: 10.1530/eje15-0296Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., & Travagli, J. et al. (2006). Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. The Journal Of Clinical Endocrinology & Metabolism, 91(8), 2892-2899. doi: 10.1210/jc.2005-2838.Pittas, A., Adler, M., Fazzari, M., Tickoo, S., Rosai, J., Larson, S., & Robbins, R. (2000). Bone Metastases from Thyroid Carcinoma: Clinical Characteristics and Prognostic Variables in One Hundred Forty-Six Patients. Thyroid, 10(3), 261268. doi: 10.1089/thy.2000.10.261. Mihailovic, J., Stefanovic, L., Malesevic, M., & Markoski, B. (2009). The Importance of Age over Radioiodine Avidity as a Prognostic Factor in Differentiated Thyroid Carcinoma with Distant Metastases. Thyroid, 19(3), 227232. doi: 10.1089/thy.2008.0186Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli ME., & Busnardo B. (1993). Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626–1631Sampson, E., Brierley, J., Le, L., Rotstein, L., & Tsang, R. (2007). Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer, 110(7), 14511456. doi: 10.1002/cncr.22956Hwang, M., Lee, E., & Yang, J. (2014). Nasolacrimal Duct Obstruction after Radioactive Iodine Therapy for Thyroid Cancer. Journal Of The Korean Ophthalmological Society, 55(1), 1. doi: 10.3341/jkos.2014.55.1.1Kloos, R., Duvuuri, V., Jhiang, S., Cahill, K., Foster, J., & Burns, J. (2002). Nasolacrimal Drainage System Obstruction from Radioactive Iodine Therapy for Thyroid Carcinoma. The Journal Of Clinical Endocrinology & Metabolism, 87(12), 5817-5820. doi: 10.1210/jc.2002-020210Mandel, S., & Mandel, L. (2003). Radioactive Iodine and the Salivary Glands. Thyroid, 13(3), 265-271. doi: 10.1089/105072503321582060Vargas H., Herrera ,J., Meza, I., & Agredo, V. (2015). Epidemiología del Cáncer de Tiroides. Medicina, 37(2),140-163.: http://revistamedicina.net/ojsanm/index.php/Medicina/article/view/109-4Xing, M. (2010). Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular And Cellular Endocrinology, 321(1), 86-93. doi: 10.1016/j.mce.2009.10.012Lim, H., Devesa, S., Sosa, J., Check, D., & Kitahara, C. (2017). Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA, 317(13), 1338-1348 doi: 10.1001/jama.2017.2719Olaleye, O., Ekrikpo, U., Moorthy, R., Lyne, O., Wiseberg, J., Black, M., & Mitchell, D. (2010). Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006. European Archives Of Oto-RhinoLaryngology, 268(6), 899-906. doi: 10.1007/s00405-010-1416-7Reynolds, R., Weir, J., Stockton, D., Brewster, D., Sandeep, T., & Strachan, M. (2005). Changing trends in incidence and mortality of thyroid cancer in Scotland. Clinical Endocrinology, 62(2), 156-162. doi: 10.1111/j.13652265.2004.02187.xHayashi, Y., Lagarde, F., Tsuda, N., Funamoto, S., Preston, D., & Koyama, K. et al. (2010). Papillary microcarcinoma of the thyroid among atomic bomb survivors. Cancer, 116(7), 1646-1655. doi: 10.1002/cncr.24872Rumyantsev, P., Saenko, V., Ilyin, A., Stepanenko, V., Rumyantseva, U., & Abrosimov, A. et al. (2011). Radiation Exposure Does Not Significantly Contribute to the Risk of Recurrence of Chernobyl Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism, 96(2), 385-393. doi: 10.1210/jc.20101634Greenspan, B. (2018). Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits. Journal Of Clinical Oncology, 36(18), 1785-1787. doi: 10.1200/jco.2018.78.6384Pitoia, F., & Miyauchi, A. (2016). 2015 American Thyroid Association Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer and Their Implementation in Various Care Settings. Thyroid, 26(2), 319-321. doi: 10.1089/thy.2015.0530Haugen, B. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer, 123(3), 372-381. doi: 10.1002/cncr.30360Van Nostrand, D. (2009). The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer. Thyroid, 19(12), 1381-1391. doi: 10.1089/thy.2009.1611Haugen, B., Alexander, E., Bible, K., Doherty, G., Mandel, S., & Nikiforov, Y. et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1-133. doi: 10.1089/thy.2015.0020Chala, A., Franco, H., Aguilar, C., & Cardona, J. (2010). Estudio descriptivo de doce años de cáncer de tiroides, Manizales, Colombia. Rev Colomb Cir,25,276289Rojas,W., Vivas-Díaz, J. (2011). Cáncer de tiroides: Características clínicas e histopatológicas servicio de endocrinología, Hospital de San José Bogotá DC, 2000-2010. Repert.med.cir, 20(3),177-184Cuervo, JA., Osorio, K., Romero, AE., Olaya, N.(2013).Caracterización clínica e histopatológica del carcinoma papilar de tiroides en el Instituto Nacional de Cancerología E.S.E., Bogotá-Colombia durante los años 2006 a 2012. Rev Col Cancerol,17(4),188Vargas, H., Herrera, J., Meza, I., & Agredo, Delgado, V. (2015). Cáncer de Tiroides e Indicaciones de Tiroidectomía. Medicina, 37(2), 109-121Mantilla-Reinaud A., Vesga-Angarita BE., Insuasty- Enríquez JS., (2006). Registro de cáncer, Unidad de Oncología, Hospital Universitario Ramón González Valencia, Bucaramanga, Colombia (1996 – 1999). MedUNAB,9,14-19.Rojas-Castillo, JC., Niño, DC., Wandurraga-Sánchez, EA., García, ME., Camacho PA., Roa, JA., Sarmiento, JG. (2015). Descripción de los hallazgos histopatológicos en la terapia inicial del cáncer de tiroides en un centro de referencia en Bucaramanga, Colombia. Rev ACE, 2(1): 40-43.Hansen, K., Timp, W., Bravo, H., Sabunciyan, S., Langmead, B., & McDonald, O. et al. (2011). Increased methylation variation in epigenetic domains across cancer types. Nature Genetics, 43(8), 768-775. doi: 10.1038/ng.865Furuya, F., Shimura, H., Suzuki, H., Taki, K., Ohta, K., Haraguchi, K., Kobayashi, T. (2004). Histone deacetylase inhibitors restore radioiodine uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroid peroxidase and thyroglobulin. Endocrinology, 145, 2865-2875Kondo, Y. (2009). Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers. Yonsei Medical Journal, 50(4), 455. http://doi.org/10.3349/ymj.2009.50.4.455Pugliese, M., Fortunati, N., Germano, A., Asioli, S., Marano, F., Palestini, N., Catalano, M. G. (2013). Histone Deacetylase Inhibition Affects Sodium Iodide Symporter Expression and Induces 131 I Cytotoxicity in Anaplastic Thyroid Cancer Cells. Thyroid, 23(7), 838-846. http://doi.org/10.1089/thy.2012.0359Vu-Phan, D., & Koenig, R. J. (2014). Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol, 386(1-2), 55-66. doi: 10.1016/j.mce.2013.07.030Russo, D., Damante, G., Puxeddu, E., Durante, C., & Filetti, S. (2011). Epigenetics of thyroid cancer and novel therapeutic targets. Journal of Molecular Endocrinology, 46(3), R73-R81. http://doi.org/10.1530/JME-10-0150Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol [Internet]. 2010;17(6):1471–4. Available from: http://www.springerlink.com/index/10.1245/s10434-010-0985-4. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39(8):699–706.Aschebrook-Kilfoy, B., Grogan, R., Ward, M., Kaplan, E., & Devesa, S. (2013). Follicular Thyroid Cancer Incidence Patterns in the United States, 1980– 2009. Thyroid, 23(8), 1015-1021. doi: 10.1089/thy.2012.0356Uribe Pérez, C., Serrano Gómez, S., & Hormiga Sánchez, C. (2018). Incidencia y mortalidad por cáncer en Bucaramanga, Colombia. 2008-2012. Colombia Médica, 49(1), 73-80Bogdanova, T., Zurnadzhy, L., Greenebaum, E., McConnell, R., Robbins, J., & Epstein, O. et al. (2006). A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident. Cancer, 107(11), 2559-2566. doi: 10.1002/cncr.22321Fagin, J. (2004). How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal Of Endocrinology, 183(2), 249-256. doi: 10.1677/joe.1.05895Kondo, T., Ezzat, S., & Asa, S. (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 6(4), 292-306. doi: 10.1038/nrc1836Suh, C., Baek, J., Choi, Y., & Lee, J. (2016). Performance of CT in the Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. American Journal Of Neuroradiology, 38(1), 154-161. doi: 10.3174/ajnr.a4967Ahn, J., Lee, J., Yi, J., Shong, Y., Hong, S., & Lee, D. et al. (2008). Diagnostic Accuracy of CT and Ultrasonography for Evaluating Metastatic Cervical Lymph Nodes in Patients with Thyroid Cancer. World Journal Of Surgery, 32(7), 15521558. doi: 10.1007/s00268-008-9588-7Noguchi, S., Noguchi, A., & Murakami, N. (1970). Papillary carcinoma of the thyroid I. Developing pattern of metastasis. Cancer, 26(5), 1053-1060. doi: 10.1002/1097-0142(197011)26:5<1053::aid-cncr2820260513>3.0.co;2-xAnda, E., Pineda, J., Toni, M., & Galofré, J. (2016). Enfermedad nodular tiroidea. Medicine - Programa De Formación Médica Continuada Acreditado, 12(13), 713-721. doi: 10.1016/j.med.2016.06.001Hegedüs, L.(2004).The Thyroid Nodule. N Engl J Med 351(17):1764–71. Doi: 10.1056/NEJMcp031436Kwak, J., Han, K., Yoon, J., Moon, H., Son, E., & Park, S. et al. (2011). Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology, 260(3), 892-899. doi: 10.1148/radiol.11110206Velasco L, S., Solar G, A., Cruz O, F., Quintana F, J., León R, A., Mosso G, L., & Fardella, C. (2007). Tiroglobulina y sus limitaciones en el seguimiento del carcinoma diferenciado del tiroides: Report of two cases. Revista Médica De Chile, 135(4). doi: 10.4067/s0034-98872007000400014Nixon, I., Whitcher, M., Palmer, F., Shaha, A., Shah, J., Patel, S., & Ganly, I. (2012). The Impact of Distant Metastases at Presentation on Prognosis in Patients Differentiated Carcinoma of the Thyroid Gland. Thyroid, 120514113505007. doi: 10.1089/thy.2011-0535Henriques de Figueiredo, B., Godbert, Y., Soubeyran, I., Carrat, X., Lagarde, P., & Cazeau, A. et al. (2014). Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients. Thyroid, 24(2), 270-276. doi: 10.1089/thy.2013.0061Elisei, R., Agate, L., Viola, D., Matrone, A., Biagini, A., & Molinaro, E. (2014). How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. Endocrinology And Metabolism Clinics Of North America, 43(2), 331-344. doi: 10.1016/j.ecl.2014.02.002Ilgan, S., Karacalioglu, A., Atac, G., Arslan, N., Ozturk, E., & Gunalp, B. et al. (2004). Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging, 31(6), 825-830. doi: 10.1007/s00259-0041460-xOta, N., Kato, K., Iwano, S., Ito, S., Abe, S., & Fujita, N. et al. (2014). Comparison of 18 F-fluoride PET/CT,18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. The British Journal Of Radiology, 87(1034), 20130444. doi: 10.1259/bjr.20130444Ito, S., Kato, K., Ikeda, M., Iwano, S., Makino, N., & Tadokoro, M. et al. (2007). Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer. Journal Of Nuclear Medicine, 48(6), 889-895. doi: 10.2967/jnumed.106.039479Salvatori, M., Biondi, B., & Rufini, V. (2015). IMAGING IN ENDOCRINOLOGY: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. European Journal Of Endocrinology, 173(3), R115-R130. doi: 10.1530/eje-15-0066Leboulleux, S., Schroeder, P., Schlumberger, M., & Ladenson, P. (2007). The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism, 3(2), 112-121. doi: 10.1038/ncpendmet0402Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J., & Talbot, M. et al. (2010). Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocrine Related Cancer, 18(1), 159-169. doi: 10.1677/erc-10-0233Robbins, R., Wan, Q., Grewal, R., Reibke, R., Gonen, M., & Strauss, H. et al. (2006). Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning. The Journal Of Clinical Endocrinology & Metabolism, 91(2), 498-505. doi: 10.1210/jc.2005-1534Olaleye, O., Ekrikpo, U., Moorthy, R., Lyne, O., Wiseberg, J., Black, M., & Mitchell, D. (2010). Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006. European Archives Of Oto-RhinoLaryngology, 268(6), 899-906. doi: 10.1007/s00405-010-1416-7Reynolds, R., Weir, J., Stockton, D., Brewster, D., Sandeep, T., & Strachan, M. (2005). Changing trends in incidence and mortality of thyroid cancer in Scotland. Clinical Endocrinology, 62(2), 156-162. doi: 10.1111/j.13652265.2004.02187.xSPECKER, B., HO, M., SPERLING, M., LADENSON, P., & ROSS, D. et al. (1998). Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid, 8(9), 737-744. doi: 10.1089/thy.1998.8.737Carhill, A., Litofsky, D., Ross, D., Jonklaas, J., Cooper, D., & Brierley, J. et al. (2015). Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987–2012. The Journal Of Clinical Endocrinology & Metabolism, 100(9), 3270-3279. doi: 10.1210/jc.2015-1346Biondi, B., & Cooper, D. (2010). Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer. Thyroid, 20(2), 135146. doi: 10.1089/thy.2009.0311Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., & Ford, R. et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer, 45(2), 228-247. doi: 10.1016/j.ejca.2008.10.026R. Shaha, A., P. Shah, J., & R. Loree, T. (1997). Differentiated thyroid cancer presenting initially with distant metastasis. The American Journal Of Surgery, 174(5), 474-476. doi: 10.1016/s0002-9610(97)00158-Cady B., Rossi R.(1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery,104:947–953. doi: 10.1067/msy.1998.93106. Cooper, D., Doherty, G., Haugen, B., Kloos, R., Lee, S., & Mandel, S. et al. (2009). Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 19(11), 1167-1214. doi: 10.1089/thy.2009.0110Watkinson, J. (2004). The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nuclear Medicine Communications, 25(9), 897-900. doi: 10.1097/00006231-200409000-00006. Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J., Wiersinga, W.(2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal Of Endocrinology, 154(6), 787-803. doi: 10.1530/eje.1.02158Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M., Nistal, M., & Santisteban, P. (2006). The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane. Endocrine-Related Cancer, 13(1), 257-269. doi: 10.1677/erc.1.01119Lin, J. (1999). Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases. Endocrine Related Cancer, 6(1), 109-115. doi: 10.1677/erc.0.0060109R. Shaha, A., P. Shah, J., & R. Loree, T. (1997). Differentiated thyroid cancer presenting initially with distant metastasis. The American Journal Of Surgery, 174(5), 474-476. doi: 10.1016/s0002-9610(97)00158-xMihailovic, J., Stefanovic, L., Malesevic, M., Erak, M., & Tesanovic, D. (2009). Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nuclear Medicine Communications, 30(7), 558-564. doi: 10.1097/mnm.0b013e32832cc2abHaq, M., & Harmer, C. (2005). Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clinical Endocrinology, 63(1), 87-93. doi: 10.1111/j.1365-2265.2005.02304.xMassin, J., Savoie, J., Garnier, H., Guiraudon, G., Leger, F., & Bacourt, F. (1984). Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer, 53(4), 982-992. doi: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-ePitoia, F., Bueno, F., & Cross, G. (2014). Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With 131IodineAvid Lung Metastasis From Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 39(9), 784-790. doi: 10.1097/rlu.0000000000000507Mihailovic, J., Stefanovic, L., Malesevic, M., Erak, M., & Tesanovic, D. (2009). Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nuclear Medicine Communications, 30(7), 558-564. doi: 10.1097/mnm.0b013e32832cc2abCho, S., Choi, H., Yeom, G., Lim, J., Moon, J., & Park, D. et al. (2014). Long-Term Prognosis of Differentiated Thyroid Cancer with Lung Metastasis in Korea and Its Prognostic Factors. Thyroid, 24(2), 277-286. doi: 10.1089/thy.2012.0654Deandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J., & Talbot, M. et al. (2010). Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocrine Related Cancer, 18(1), 159169. doi: 10.1677/erc-10-0233Miyauchi, A., Kudo, T., Miya, A., Kobayashi, K., Ito, Y., & Takamura, Y. et al. (2011). Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy. Thyroid, 21(7), 707-716. doi: 10.1089/thy.2010.0355Lin JD, Chao TC, Chou SC, et al. Papillary thyroid carcinomas with lung metastases. Thyroid 2004;14:1091–6Leite AK, Kulcsar MA, de Godoi Cavalheiro B, de Mello ES, Alves VA, Cernea CR, Matos LL. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER. Endocr Pract. 2017 Jan;23(1):72-78Boria, A.J., Perez-Torres, C.J. Minimal difference between fractionated and single-fraction exposure in a murine model of radiation necrosis. Radiat Oncol 14, 144 (2019).Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G: Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16: 3100-3104. 10.1158/1078-0432.CCR-09-2891Rubner, Y., Muth, C., Strnad, A. et al. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol 9, 89 (2014Terashima, S., Hosokawa, Y., Tsuruga, E., Mariya, Y., & Nakamura, T. (2017). Impact of time interval and dose rate on cell survival following low-dose fractionated exposures. Journal of radiation research, 58(6), 782–790Adamczewski, Z., Stasiołek, M., Karwowski, B., Dedecjus, M., OrszulakMichalak, D., Merecz, A., Śliwka, P. W., Puła, B., & Lewiński, A. (2015). The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro. International journal of molecular sciences, 16(7), 14608–14622Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352–9Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 2007;66:58–64Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22:884–9Li YR, Chen ST, Hsueh C, Chao TC, Ho TY, Lin JD. Risk factors of distant metastasis in the follicular variant of papillary thyroid carcinoma. J Formos Med Assoc. 2016 Aug;115(8):665-71.ORIGINAL2021_Tesis_Liliana_Patricia_Torres.pdf2021_Tesis_Liliana_Patricia_Torres.pdfTesisapplication/pdf1773705https://repository.unab.edu.co/bitstream/20.500.12749/14233/1/2021_Tesis_Liliana_Patricia_Torres.pdf3b2282b0ca8f63e604aa5b0ff908d996MD51open access2021_Licencia_Liliana_Patricia_Torres.pdf2021_Licencia_Liliana_Patricia_Torres.pdfLicenciaapplication/pdf100691https://repository.unab.edu.co/bitstream/20.500.12749/14233/2/2021_Licencia_Liliana_Patricia_Torres.pdfc5688f2125fdb04a89bceca69fa2367fMD52metadata only accessLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repository.unab.edu.co/bitstream/20.500.12749/14233/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53open accessTHUMBNAIL2021_Tesis_Liliana_Patricia_Torres.pdf.jpg2021_Tesis_Liliana_Patricia_Torres.pdf.jpgIM Thumbnailimage/jpeg6231https://repository.unab.edu.co/bitstream/20.500.12749/14233/4/2021_Tesis_Liliana_Patricia_Torres.pdf.jpg850e7f21791bcbcac7b6982c006979a7MD54open access2021_Licencia_Liliana_Patricia_Torres.pdf.jpg2021_Licencia_Liliana_Patricia_Torres.pdf.jpgIM Thumbnailimage/jpeg9961https://repository.unab.edu.co/bitstream/20.500.12749/14233/5/2021_Licencia_Liliana_Patricia_Torres.pdf.jpgca8ea159b6fb428e6abe6528620fde30MD55metadata only access20.500.12749/14233oai:repository.unab.edu.co:20.500.12749/142332024-01-18 11:20:52.254open accessRepositorio Institucional \| Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=

Factores asociados a remisión imagenológica funcional completa en pacientes con carcinoma diferenciado de tiroides tratados con yodo radiactivo para manejo de metástasis pulmonares

Publicaciones similares